Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00367887 | A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects | PHASE2 | COMPLETED | 246 | — | — | Oct 1, 2006 | Jul 1, 2008 | Feb 11, 2013 | 35 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Peg-Intron | DRUG | SC injection, weight based dosing, weekly, 48 weeks |
| REBETOL | DRUG | Capsules, weight based dosing, Q12 hrs daily, 48weeks |
| HCV 796 | DRUG | Capsules, 500 mg, Q 12 hrs. daily, 48 weeks |
Inclusion Criteria: * Infection with HCV genotype 1. * HCV- infected subjects naive to treatment. * HCV-infected non-responder subjects. Exclusion Criteria: * Women who are pregnant or breastfeeding. * ALT \>/ or = 5X the upper limit of normal. * AST \>/ or = 5X the upper limit of normal.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |